Zaltrap Purple Book BLA 125418

BLA number
125418
Proprietary names
Zaltrap
Proper names
Ziv-Aflibercept
Applicant
Sanofi-Aventis U.S. LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001ZaltrapZiv-Aflibercept351(a)100MG/4ML (25MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2012-08-03
002ZaltrapZiv-Aflibercept351(a)200MG/8ML (25MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2012-08-03

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Zaltrap351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U002Zaltrap351(a)RxSanofi-Aventis U.S. LLC
2020-05-01R001Zaltrap351(a)Rxsanofi-aventis U.S. LLC
2020-05-01R002Zaltrap351(a)Rxsanofi-aventis U.S. LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Zaltrap351(a)RxLicensed2012-08-03
2020-05-01002Zaltrap351(a)RxLicensed2012-08-03